Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don’t agree.
Ok. I can accept it’s related to ENZC. Thanks for pointing it out to me.
Good point Jack. Thanks for pointing that out. Guess I’m hyper sensitive to speculation these days. Lol.
It all works for me. Looks the same. I wouldn’t speculate on that. Also I wouldn’t speculate on this guys big news. Didn’t he tweet an hour later. Maybe that was his big news. Also why assume or even speculate that his news is related to enzc.
How about you prove that they are not. Exactly.
Just hold tight imo. End of June things will look different if they have in fact competed most of the filings. I get that they might not be on track to the exact timeline they suggested but close would make a huge difference.
Next filing is due by end of month. Could come later but wait for that as the next step. All is good. Let their plan unfold.
Won’t matter at all by the end of the year. Sooner than that most likely. Though I guess manipulation will still occur, but we won’t be talking about the same pps amounts if the company keeps progressing the way it has been.
I agree. It is inevitable. I’m ok with how other people trade. The longer hold works better for me. I find companies that will do well, buy lots of shares, wait, and reap the rewards. That’s my basic formula.
In terms of the timeline I’m excited that primate trials are so close.
Yes, now I clearly see that patience, holding, adding is an easy strategy here. As milestones hit, it’s going to continue to build legitimacy. This will bring more partnership interest and trust from both investors, government, and business. It’s exponential imo. Just wait.
I agree. Now I can see how the licensing a d partnerships will set up. They will be producing mAbs for many diseases for many companies in a massively growing market for mAbs with the right experts in hiv, cancer, AI, patent expertise, and the funding process supporting/backing them all the way.
People are seeing more and more the longer they look. The foundation and details are now confirmed whereas before there was some discussion and argumentation. We have a clearer picture now.
Well I think if you take a big picture view then I think it’s going up in the long run. Tomorrow won’t determine that.
How did you find out what the mega news this week will be and how do you know it will be released this week?
You personally? Why?
If people stop selling the price will stabilize. That being said, buying would need to happen as well. The low priced shares are definitely being bought up.
Do you think this will actually change anything?
Is it not also people selling based on panic or rational realization that they could lose more profits? I get that the panic can also be supported by mm’s but I would also imagine investors themselves do have control in that they can decided to sell or buy. Won’t the price will level out once selling stops and buying begins?
Company targets for filings by these dates.
April 30th 2019 annual report
May 30th Q1,2,3 reports
June 15th 2020 annual
June 30th Q1 report
Here is the presentation from the other day.
Chris Jarvis ex vp
Anyone check out info about the two new people on the advisory board? Maybe this has already been discussed.
Ellen Vitetta
https://en.m.wikipedia.org/wiki/Ellen_Vitetta
Yvonne Bryson
https://www.uclahealth.org/yvonne-bryson
Looks likes two great additions to me. I wonder why they specifically chose them?
My discussion has nothing to do with charts, just using accurate language. If the discussion is about charts, then we should also use accurate language. I agree.
What does the timeline consist of for Clone 3 in terms of how you get to 10 years? I think you would need very accurately sourced information to be able to make that statement. Also remember that Big Pharma could be interested at the animal trial stage.
ITV in the EMA. Charles said market authorization could be in 1-1.5 years. This is the focus as it is what the revenue projections are based on. They have funded trials. The next step could/would be partnership etc to bring it to market like you suggested.
You believe or feel it has been a Ponzi scheme. That is something you believe or feel. Sorry, just making sure we’re all trying to use accurate language.
I personally disagree. I stated in a previous post the pathway the company has taken and that based on history and current state of operations and vision, the company looks like a very good investment for a small biotech.
Yes. That’s another important point to keep being reminded of. Fully funded clinical trials.
Sorry for entering this conversation. I didn’t read all the threads. The info you have in your last post is not accurate. They are not in the early stages of trials. They have been developing and have gone through many stages of the development process for both ITV 1 and clone 3. They are in fact at the final stages of the process the precedes commercializations or a stage where other companies could enter based on a mutual interest in joining in to potentially create profit for their company.
They would not have to do the entire process to get fda if they were successful with the EMA process. The agencies have a mutual recognition agree to avoid unnecessary duplication and delay in bringing drugs etc to market.
Under the current suggestion by the company, ITV 1 could be to market in 1-1.5 years. That is a very short time frame in the biotech world.
I’m not sure about the timeline for clone3 but the process to human clinical trials has been very clearly explained. France, animal trials in California, and then human. It has been suggested by the company that big pharma could be interested during or after the animal phase.
Also, many things to do with patents of mAbs, conserved sites of viruses, and the innovative use of AI could potentially bring interest at any stage.
The company has also demonstrated an interest in creating a better company through transparency of filing, uplisting, and auditing their financials.
On paper, this looks like a great opportunity in my opinion. Just trying to put forward what I see as accurate information.
Curious as to why you aren’t selling if you think this is going to a penny? Or are you just venting?
What it says to me is that people have said nice things to him but are not interested. It’s possible they could be once they are farther along in their science.
You’ll be sleeping for ever man. Fyi.
I think it’s clear a bp partner is not happening any time soon. Charles was clear about that. It’s the small steps of progress in trails that makes sense to focus on now. If In 6 months we are still doing that, which I’m confident we will be, then pps will catch up to progress of the science.
What type of problem?
I agree with the concept of different types of investors coming in at different stages. This aspect of the process is very interesting in the evolution of a stock. Many otc stocks don’t go through this and mature as the companies themselves don’t mature. Enzolytics has been maturing for years. At this stage they are filing and progressing through the scientific process and associated processes to build a real biotech company. The audits and uplisting will continue this maturing in the right direction and with that will come different types of investors.
In time, if or when they get to animal trials and complete the trials for ITV 1, things will get even more serious. Also, patents, collaborations, and partnerships could evolve at any time for different aspects of their operation.
The otc hype part with all the unknowns has mostly ended. What remains is a legitimate company with international connections, that is in the final stages of making an attempt to establish a successful (with the potential for massive revenue) biotech company.
Looking forward to the next year of ENZC.
I doubt it. There would be no basis for a penny. Unless you have a valid reason?
The trials already competed make it so they can submit an application for a validation of what was already complete. Once validation is received this makes it so they can get a CTA (I think that is the acronym. Clinical trials application I assume) to begin clinical trials under the EMA. They basically skip to the last part of the process. This is for ITV 1 and is expected to be competed within 18 months.
For clone 3 animal trials. Not sure if it would/could happen during or after. Probably either is possible. He didn’t mention anything about when others could be interested in itv1 or other patents like the ones for Covid.
Wow. You’re planning to stick around for a long time.
True. I’m really wondering the timeline for the trials in France that then lead to the animal trials. That is a more interesting story.
Nope. That being said, a real company at work here with incredible revenue planned. Potential to create massive revenue for themselves and other companies. 100b over 11 years with 1 product. They have applied for patents for their covid mAbs and these could be of interest to another company in the near term. Almost at primate stage for clone 3 (after trials in France) which big pharma has said they would be interested around this time. This company is global and will create pps value in the short term. Big value. Not today though and that is ok. I would rather trust the company I’m invested in rather than have my investment in question.
What testing? Clinical trials for ITV 1 will start in about 5 months. They will be compete in 1.5 years.
The clinical testing ivt 1 is projected to be competed in 1-1.5 years from now. I would lean towards the longer time to be safe.
No we already determined a lot of this is inaccurate and updated through other posts. Just trying to keep information correct. Thanks.
I watched it again. Thanks for the link. I would think that Big Pharma could become interested in ITV-1 before the 1.5 year completion estimate based on the fact they said they could be interested in clone3 at/after animal trials.
I also wonder what happens with the covid mAbs once the patent is approved...and how long does this take? Could a company use them or add them to their already approved treatment with less testing or accelerated testing based on their connections or processes in place to speed this up because of covid.
Either way, I feel a lot will develop and happen between now and the next two years. They are projecting to create as much revenue as Gilead and Merck once they are up and running....though I imagine their plan is to partner, licence and make some of that revenue.
Itv 1 - HIV
2 patents
Clinically tested under EU standard
Cost interfered and not completed
80% drop in viral load etc…
Preparing to conduct new trials EMA
Partnership with EU businessmen
They will pay for the clinical trials
EU and asia distribution
FDA recognition could also happen after EMA validation order in a few months but not the focus because EMA is quicker
Clinical trials begin in 4 or 5 months….validation order first
Clinical trails could be finished in 1.5 years from now and ready for market
Clone 3 mAbs - HIV
Clone 3 has been tested in 5 labs around the world
Neutralized 95% of isolates it was tested against
First U of Strasbourg France
Then animal trials in California (Big Pharma suggested they would begin to be interested at this stage)
Then human trials
To market if successful
Covid mAbs
Have submitted patent applications for both mAbs and conserved sites discovered
Have started to produce the mAbs
Could be used by other companies in a “cocktail” treatment